search
Back to results

Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries

Primary Purpose

Flexor Tendon

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Standard of Care Surgical Procedure
VersaWrap Treatment
Sponsored by
University of Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Flexor Tendon

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients presenting to the plastic surgery service with a zone 2 flexor tendon injury requiring surgical repair

Exclusion Criteria:

  • Patients with a sensitivity or allergy to polysaccharides alginate, hyaluronic acid, or citrate

    • Patients with psychiatric or medical problems that preclude them from having surgery
    • Female patients that are pregnant or breastfeeding
    • Prisoners
    • Patients who are unwilling or unable to follow-up

Sites / Locations

  • University of FloridaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group A

Group B

Arm Description

VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap

Standard of Care Treatment Arm- Zone 2 flexor tendon repair

Outcomes

Primary Outcome Measures

Strickland modified Total Active Motion (TAM)
This is an objective assessment of range of motion of the finger (physiological parameter)

Secondary Outcome Measures

Full Information

First Posted
March 24, 2020
Last Updated
June 5, 2023
Sponsor
University of Florida
search

1. Study Identification

Unique Protocol Identification Number
NCT04322370
Brief Title
Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries
Official Title
Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 21, 2020 (Actual)
Primary Completion Date
May 17, 2024 (Anticipated)
Study Completion Date
May 17, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
To analyze outcomes between patients with Z2FT injuries following repair, randomized to two groups. The first group will be the negative control, with no tendon wrap. The second group will have a VersaWrap Tendon Protector applied over the site of the tendon repair. VersaWrap is current SOC at UF.
Detailed Description
VersaWrap Tendon Protector is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue. It functions by separating the healing tendon from surrounding tissues to facilitate tendon gliding and tendon healing. VersaWrap can be placed on, over, or around flexor tendons and remains in place until healing is complete and then is bioresorbed. VersaWrap is FDA cleared for the use in procedures where there is no significant loss of tendon tissue and is currently one of the standard of care treatments used for this injury at UF Health. VersaWrap Tendon Protector includes a bioresorbable hydrogel sheet and a wetting solution. The sheet is transparent, flexible, ultrathin, non-sided, and can be cut to the desired size. It is made of polysaccharides alginate and hyaluronic acid. Tendon adhesions are a major problem following repair, particularly for zone 2 flexor tendon (Z2FT) lacerations. The purpose of this study is to prospectively analyze outcomes between patients with Z2FT injuries following repair, randomized to two groups. The first group will be the negative control, with no tendon wrap. The second group will have a VersaWrap Tendon Protector applied over the site of the tendon repair. Outcomes will be evaluated during standard of care post-operative clinic visits at 2 (+/-10 days) weeks, 6 weeks (+/-2 weeks) and 3 months (+/- 1 month) following surgery. Data will be collected from standard of care measurements that include the following outcome measures that will be performed at each follow up visit: range of motion of the affected finger at different joints; total active motion (TAM) of the finger; Strickland modification of TAM (only including proximal interphalangeal (PIP); and distal interphalangeal (DIP) joints), as well as, DASH score and Michigan Hand Outcomes questionnaire. A measurement of grip strength will be obtained at the 3 month follow up visit. This is an important study as adhesions are a particularly serious problem following repair of Z2FT injuries, which can result in persistent finger stiffness and decreased range of motion reducing the quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Flexor Tendon

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care Provider
Masking Description
The Occupational hand therapists will be blinded to the use of VersaWrap.
Allocation
Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Standard of Care Treatment Arm- Zone 2 flexor tendon repair
Intervention Type
Procedure
Intervention Name(s)
Standard of Care Surgical Procedure
Intervention Description
Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
Intervention Type
Device
Intervention Name(s)
VersaWrap Treatment
Intervention Description
is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
Primary Outcome Measure Information:
Title
Strickland modified Total Active Motion (TAM)
Description
This is an objective assessment of range of motion of the finger (physiological parameter)
Time Frame
At 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients presenting to the plastic surgery service with a zone 2 flexor tendon injury requiring surgical repair Exclusion Criteria: Patients with a sensitivity or allergy to polysaccharides alginate, hyaluronic acid, or citrate Patients with psychiatric or medical problems that preclude them from having surgery Female patients that are pregnant or breastfeeding Prisoners Patients who are unwilling or unable to follow-up
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tera Thigpin
Phone
3522652393
Email
tera.thigpin@surgery.ufl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harvey Chim, MD
Organizational Affiliation
University of Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Harvey Chim, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries

We'll reach out to this number within 24 hrs